News
Obagi Medical Products' Solubilized Benzoyl Peroxide Provides Clinically Significant Lesion Reduction for Mild to Moderately Severe Acne
Data from four studies show significant acne lesion reduction and patient satisfaction with the use of CLENZIderm M.D. Acne Therapeutic Systems on all skin types
Obagi Medical Products, Inc. , a leader in topical aesthetic and therapeutic skin health systems, announced the results of four studies of the CLENZIderm M.D.(TM) Acne Therapeutic Systems' two proprietary 3-step acne treatments, today at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio. The data show that patients of all skin types with mild-to-moderately severe acne saw significant improvement in inflammatory and non-inflammatory lesions and reported high levels of patient satisfaction, lower levels of dryness and greater comfort when using the innovative formulation of solubilized 5% benzoyl peroxide (BPO) in the CLENZIderm M.D.(TM) Systems.
Key findings of the studies:
Two Studies of the Solubilized 5% BPO Serum Gel for Normal-to-Oily Skin
- The first study showed that when compared to twice-daily treatment with a leading BPO/clindamycin combination product, the twice-daily monotherapy with the solubilized 5% BPO serum gel (CLENZIderm M.D.) resulted in a greater and more rapid reduction in the number of non-inflammatory and inflammatory lesions (42% vs. 28% and 70% vs. 61%, respectively, at week 4).
- The second study showed that the 3-step CLENZIderm M.D. System demonstrated a moderate or greater overall improvement compared with previously used treatments and high patient satisfaction. A majority (up to 77%) of patients who participated in this multicenter observation study considered the CLENZIderm M.D. acne system more effective than prescription and over-the-counter acne medications they had used previously.
Two Studies of the Solubilized 5% BPO Lotion for Normal-to-Dry Skin
- In the first study, the investigator found that compared to a leading BPO/clindamycin combination product, the once-daily use of CLENZIderm M.D. System for normal-to-dry skin provided comparable improvements by reducing the non-inflammatory count by a mean of 38% and reducing the inflammatory lesion count by a mean of 63% (versus 48% and 66%,respectively, with BPO/clindamycin).
-- Patient ratings also showed that the 3-step solubilized 5% BPO Lotion system was as effective as the BPO/clindamycin combination product and, on a scale of 0(poor) - 4(excellent), achieved a relatively greater improvement in mean score for:
-- Effectiveness of treatment between baseline and week 4 (from 2.5 to 3.4 with the acne system versus 2.5 to 2.9 with BPO/clindamycin)
-- Reduction of acne (from 1.6 to 3.1 with the acne system versus 1.8 to 2.6 with BPO/clindamycin)
- In the second study comparing the CLENZIderm M.D. System for normal-to-dry skin to a BPO/clindamycin combination product for patient tolerability, the 3-step system demonstrated lower levels of dryness (P less than or equal to .05) after 2 weeks.